A Phase II Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy : Nick Name - ICING Study
Latest Information Update: 27 Sep 2021
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Extranodal NK-T-cell lymphoma; Large granular lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms ICING
- 22 Sep 2021 Status changed from not yet recruiting to recruiting.
- 25 Feb 2021 New trial record